For the patients with hypersecreting postoperative remnant tumor, those with low chance of surgical cure (i.e. cavernous sinus invasion) or with comorbidities that lead to contraindication of operation, medical therapies are available, grouped into three classes: somatostatin receptor analogues, dopamine agonists (DA) and GH receptor antagonists. This evidence concerns the gene GHR and neoplasm.